Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic
By Elias Schisgall
The Canadian government authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories, making it the first G7 country to approve a generic version of the massively popular GLP-1 diabetes treatment.
The generic semaglutide injection is modeled off of Novo Nordisk's Ozempic and is approved for once-weekly treatment of adults with type 2 diabetes.
Health Canada, the country's health-policy arm, said it is reviewing eight other submissions for generic GLP-1 treatments and expects to make regulatory decisions in the coming weeks and months.
The approval opens the door for Canadian patients to receive the treatment at lower costs than those offered by Novo Nordisk and its main GLP-1 competitor, Eli Lilly. Both companies have reaped windfalls from the rapid adoption of their diabetes and obesity treatments.
Some generic medications in Canada can be 45% to 90% cheaper than their brand name equivalents, Health Canada said.
American depositary shares of Novo Nordisk were down 3%, to $39.94, midday Wednesday. Eli Lilly was down 2.3%, to $855.13, and is expected to report its first-quarter results Thursday morning.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
April 29, 2026 12:37 ET (16:37 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States